Ocugen (OCGN) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zura Bio (ZURA) has outperformed Ocugen (OCGN) over the past year, losing 11.3% versus a loss of 47.8%. Zura Bio is the larger company by market cap ($383.3 million vs $324.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCGN | ZURA |
|---|---|---|
| Share price | $0.9555 | $4.00 |
| Market cap | $324.02M | $383.32M |
| 1-day change | -2.24% | -3.15% |
| YTD return | -29.22% | -23.66% |
| 1-year return | -47.79% | -11.31% |
| 5-year return | -88.97% | — |
| EPS (TTM) | $-0.25 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $7.44 |
| 52-week low | $0.90 | $3.15 |
| Distance from 52-week high | -64.94% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1173.68% | +350.00% |
| Average volume | 6.06M | 1.44M |
| Shares outstanding | 339.11M | 95.83M |
| Employees | 116 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZURA has outperformed OCGN by 36.5 percentage points over the past year.
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
OCGN vs ZURA FAQ
Which is bigger, Ocugen or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $324.02M for Ocugen (OCGN).
Which stock has performed better over the past year, OCGN or ZURA?
ZURA returned -11.31% over the past 12 months, compared with -47.79% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Ocugen and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.